SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: semi_infinite who wrote (978)9/12/2000 5:21:18 PM
From: Pluvia   of 1766
 
1. why did Roche fund manufacturing facilities despite the uncertainties?

Roche is handling the Phase III trials, without drugs they can't do the trials. None of that has anything to do with the fact that Phase II study designs were flawed.

2. why would the FDA let trms proceed with phase III without clarifying the phase II issues that you described?

I expect this to be resolved in Phase III. As a result I expect Phase III results to be worse not better than Phase II results. This is because Phase II results included benefit from the other cocktail of anti-HIV drugs used.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News